https://www.rigel.com/ https://www.rigel.com/who-we-are https://www.rigel.com/who-we-are/overview https://www.rigel.com/who-we-are/management-team https://www.rigel.com/who-we-are/board-of-directors https://www.rigel.com/who-we-are/partners https://www.rigel.com/pipeline https://www.rigel.com/pipeline/clinical-programs/irak14-inhibitor https://www.rigel.com/pipeline/clinical-programs/ripk1-inhibitor /who-we-are/partners https://www.rigel.com/pipeline/clinical-trials https://www.rigel.com/pipeline/investigator-sponsored-research https://www.rigel.com/pipeline/expanded-access-policy https://www.rigel.com/products https://www.rigel.com/join-our-team https://www.rigel.com/news-media/press-releases/detail/434/rigel-announces-publication-of-final-arrow-clinical-trial https://www.rigel.com/news-media/press-releases/detail/433/rigel-provides-fourth-quarter-and-full-year-2025-financial https://www.rigel.com/news-media/press-releases/detail/432/rigel-announces-conference-call-and-webcast-to-report https://www.rigel.com/news-media/press-releases/detail/431/rigel-appoints-michael-p-miller-to-the-board-of-directors https://www.rigel.com/news-media/press-releases/detail/430/rigel-provides-business-update-and-2026-outlook https://www.rigel.com/news-media/press-releases/detail/429/rigel-pharmaceuticals-inc-announces-inducement-grants https://www.rigel.com/news-media/press-releases/detail/428/rigel-to-present-at-the-44th-annual-j-p-morgan-healthcare https://www.rigel.com/news-media/press-releases/detail/427/rigel-presents-updated-data-from-the-ongoing-phase-1b-study https://www.rigel.com/news-media/press-releases/detail/426/rigel-to-present-at-the-piper-sandler-37th-annual https://www.rigel.com/news-media/press-releases/detail/425/rigel-announces-publication-of-final-5-year-data-on https://www.rigel.com/news-media/press-releases/detail/424/rigel-to-present-at-the-jefferies-global-healthcare https://www.rigel.com/news-media/press-releases/detail/423/rigel-reports-third-quarter-2025-financial-results-and https://www.rigel.com/news-media/press-releases/detail/422/rigel-announces-one-oral-and-four-poster-presentations-at https://www.rigel.com/news-media/press-releases/detail/421/rigel-announces-conference-call-and-webcast-to-report-third https://www.rigel.com/news-media/press-releases/detail/420/rigel-announces-first-patient-enrolled-in-the-dose https://www.rigel.com/news-media/press-releases/detail/419/rigel-to-participate-in-upcoming-september-investor https://www.rigel.com/news-media/press-releases/detail/418/rigel-reports-second-quarter-2025-financial-results-and https://www.rigel.com/news-media/press-releases/detail/417/rigel-announces-conference-call-and-webcast-to-report https://www.rigel.com/news-media/press-releases/detail/416/rigel-to-present-at-the-jefferies-global-healthcare https://www.rigel.com/news-media/press-releases/detail/415/rigel-announces-poster-presentations-at-the-2025-asco https://www.rigel.com/news-media/press-releases/detail/414/rigel-reports-first-quarter-2025-financial-results-and https://www.rigel.com/news-media/press-releases/detail/413/rigel-announces-conference-call-and-webcast-to-report-first https://www.rigel.com/news-media/press-releases/detail/412/rigel-announces-settlement-agreement-resolving-tavalisse https://www.rigel.com/news-media/press-releases/detail/411/rigel-appoints-mark-w-frohlich-m-d-to-board-of-directors https://www.rigel.com/news-media/press-releases/detail/410/rigel-reports-fourth-quarter-and-full-year-2024-financial https://www.rigel.com/news-media/press-releases/detail/409/rigel-announces-conference-call-and-webcast-to-report https://www.rigel.com/news-media/press-releases/detail/408/rigels-fostamatinib-being-studied-by-national-institute-of https://www.rigel.com/news-media/press-releases/detail/407/rigel-provides-business-update-and-2025-outlook https://www.rigel.com/news-media/press-releases/detail/406/rigel-announces-r289-granted-orphan-drug-designation-by-the https://www.rigel.com/news-media/press-releases/detail/405/rigel-to-present-at-the-43rd-annual-j-p-morgan-healthcare https://www.rigel.com/news-media/press-releases/detail/404/rigel-highlights-initial-data-from-ongoing-phase-1b-study https://www.rigel.com/news-media/press-releases/detail/403/rigel-announces-r289-granted-fast-track-designation-by-the https://www.rigel.com/news-media/press-releases/detail/402/rigel-to-present-at-the-jefferies-london-healthcare https://www.rigel.com/news-media/press-releases/detail/401/rigel-reports-third-quarter-2024-financial-results-and https://www.rigel.com/news-media/press-releases/detail/400/rigel-announces-six-poster-presentations-at-the-66th https://www.rigel.com/news-media/press-releases/detail/399/rigel-announces-conference-call-and-webcast-to-report-third https://www.rigel.com/news-media/press-releases/detail/398/rigel-pharmaceuticals-issues-dear-healthcare-provider https://www.rigel.com/news-media/press-releases/detail/397/rigel-to-present-at-the-2024-cantor-global-healthcare https://www.rigel.com/news-media/press-releases/detail/396/rigel-announces-first-patient-enrolled-in-phase-1b2 https://www.rigel.com/news-media/press-releases/detail/395/rigel-expands-relationship-with-kissei-to-include https://www.rigel.com/news-media/press-releases/detail/394/rigel-to-participate-in-upcoming-september-investor https://www.rigel.com/news-media/press-releases/detail/393/rigel-reports-second-quarter-2024-financial-results-and https://www.rigel.com/news-media/press-releases/detail/392/rigel-announces-conference-call-and-webcast-to-report https://www.rigel.com/news-media/press-releases/detail/391/rigel-announces-reverse-stock-split https://www.rigel.com/news-media/press-releases/detail/390/rigel-pharmaceuticals-completes-transfer-of-gavreto https://www.rigel.com/news-media/press-releases/detail/389/rigel-announces-five-presentations-at-the-eha2024-hybrid https://www.rigel.com/news-media/press-releases/detail/388/rigel-highlights-new-data-in-three-poster-presentations-at https://www.rigel.com/news-media/press-releases/detail/387/rigel-to-present-at-the-jefferies-global-healthcare https://www.rigel.com/news-media/press-releases/detail/386/rigel-announces-presentations-at-the-upcoming-2024-asco https://www.rigel.com/news-media/press-releases/detail/385/rigel-reports-first-quarter-2024-financial-results-and https://www.rigel.com/news-media/press-releases/detail/384/rigel-announces-conference-call-and-webcast-to-report-first https://www.rigel.com/news-media/press-releases/detail/383/rigel-announces-publication-of-data-on-rezlidhia https://www.rigel.com/news-media/press-releases/detail/382/rigel-pharmaceuticals-announces-appointment-of-lisa https://www.rigel.com/news-media/press-releases/detail/381/rigel-reports-fourth-quarter-and-full-year-2023-financial https://www.rigel.com/news-media/press-releases/detail/380/rigel-announces-conference-call-and-webcast-to-report https://www.rigel.com/news-media/press-releases/detail/379/rigel-pharmaceuticals-acquires-u-s-rights-to-gavreto https://www.rigel.com/news-media/press-releases/detail/378/rigel-pharmaceuticals-provides-business-update https://www.rigel.com/news-media/press-releases/detail/376/rigel-announces-collaboration-with-connect-to-conduct-a https://www.rigel.com/news-media/press-releases/detail/375/rigel-to-present-at-the-42nd-annual-j-p-morgan-healthcare https://www.rigel.com/news-media/press-releases/detail/374/rigel-pharmaceuticals-and-md-anderson-announce-strategic https://www.rigel.com/news-media/press-releases/detail/373/rigel-reports-third-quarter-2023-financial-results-and https://www.rigel.com/news-media/press-releases/detail/372/rigel-to-present-at-the-jefferies-london-healthcare https://www.rigel.com/news-media/press-releases/detail/371/rigel-announces-poster-presentations-at-the-65th-american https://www.rigel.com/news-media/press-releases/detail/370/rigel-announces-conference-call-and-webcast-to-report-third https://www.rigel.com/news-media/press-releases/detail/369/rigel-announces-presentation-at-the-upcoming-idweek-2023 https://www.rigel.com/news-media/press-releases/detail/367/rigel-to-present-at-the-2023-cantor-global-healthcare https://www.rigel.com/news-media/press-releases/detail/366/rigel-to-participate-in-upcoming-september-investor https://www.rigel.com/news-media/press-releases/detail/365/rigel-reports-second-quarter-2023-financial-results-and https://www.rigel.com/news-media/press-releases/detail/364/rigel-announces-conference-call-and-webcast-to-report https://www.rigel.com/news-media/press-releases/detail/363/rigel-announces-presentation-of-data-from-analysis-of https://www.rigel.com/news-media/press-releases/detail/362/rigel-announces-second-rezlidhia-olutasidenib https://www.rigel.com/news-media/press-releases/detail/361/rigel-announces-poster-presentation-at-the-upcoming-2023 https://www.rigel.com/news-media/press-releases/detail/360/rigel-to-present-at-the-jefferies-2023-global-healthcare https://www.rigel.com/news-media/press-releases/detail/359/rigel-reports-first-quarter-2023-financial-results-and https://www.rigel.com/news-media/press-releases/detail/358/rigel-announces-conference-call-and-webcast-to-report-first https://www.rigel.com/news-media/press-releases/detail/356/rigel-reports-fourth-quarter-and-full-year-2022-financial https://www.rigel.com/news-media/press-releases/detail/355/rigel-announces-conference-call-and-webcast-to-report https://www.rigel.com/news-media/press-releases/detail/354/rigel-announces-publication-of-rezlidhia-olutasidenib https://www.rigel.com/news-media/press-releases/detail/353/national-comprehensive-cancer-network-adds-newly-approved https://www.rigel.com/news-media/press-releases/detail/352/rigel-pharmaceuticals-provides-business-update https://www.rigel.com/news-media/press-releases/detail/351/rigel-announces-availability-of-rezlidhia-olutasidenib https://www.rigel.com/news-media/press-releases/detail/350/rigel-doses-first-patient-in-phase-1b-study-of-r289-for-the https://www.rigel.com/news-media/press-releases/detail/349/rigel-announces-u-s-fda-approval-of-rezlidhia https://www.rigel.com/news-media/press-releases/detail/348/rigel-announces-publication-of-early-clinical-data-of https://www.rigel.com/news-media/press-releases/detail/347/rigel-reports-third-quarter-2022-financial-results-and https://www.rigel.com/news-media/press-releases/detail/346/rigel-announces-five-poster-presentations-at-the-upcoming https://www.rigel.com/news-media/press-releases/detail/345/rigel-announces-top-line-results-from-focus-phase-3 https://www.rigel.com/news-media/press-releases/detail/344/rigel-announces-conference-call-and-webcast-to-report-third https://www.rigel.com/news-media/press-releases/detail/343/rigel-provides-update-on-plans-for-snda-for-waiha-program https://www.rigel.com/news-media/press-releases/detail/342/rigel-to-present-at-the-h-c-wainwright-24th-annual-global https://www.rigel.com/news-media/press-releases/detail/341/rigel-reports-second-quarter-2022-financial-results-and https://www.rigel.com/news-media/press-releases/detail/340/rigel-pharmaceuticals-and-forma-therapeutics-announce https://www.rigel.com/news-media/press-releases/detail/339/rigel-announces-conference-call-and-webcast-to-report https://www.rigel.com/news-media/press-releases/detail/338/rigel-announces-top-line-results-from-forward-phase-3 https://www.rigel.com/news-media/press-releases/detail/337/rigel-reports-first-quarter-2022-financial-results-and https://www.rigel.com/news-media/press-releases/detail/336/rigel-announces-conference-call-and-webcast-to-report-first https://www.rigel.com/news-media/press-releases/detail/335/rigel-announces-publication-of-data-from-phase-2-clinical https://www.rigel.com/news-media/press-releases/detail/334/rigel-reports-fourth-quarter-and-full-year-2021-financial https://www.rigel.com/news-media/press-releases/detail/333/rigel-announces-conference-call-and-webcast-to-report https://www.rigel.com/news-media/press-releases/detail/332/rigel-to-present-at-the-j-p-morgan-healthcare-conference https://www.rigel.com/news-media/press-releases/detail/331/rigel-pharmaceuticals-provides-business-update https://www.rigel.com/news-media/press-releases/detail/330/fostamatinib-meets-primary-endpoint-in-phase-3-trial-in https://www.rigel.com/news-media/press-releases/detail/329/rigel-appoints-kamil-ali-jackson-to-board-of-directors https://www.rigel.com/news-media/press-releases/detail/328/rigel-sharpens-focus-on-its-advanced-portfolio-opportunities https://www.rigel.com/news-media/press-releases/detail/327/rigel-to-participate-in-two-upcoming-investor-conferences https://www.rigel.com/news-media/press-releases/detail/326/rigel-reports-third-quarter-2021-financial-results-and https://www.rigel.com/news-media/press-releases/detail/325/rigel-announces-conference-call-and-webcast-to-report-third https://www.rigel.com/news-media/press-releases/detail/324/grifols-begins-commercializing-tavlesse-in-france-italy https://www.rigel.com/news-media/press-releases/detail/323/rigel-to-participate-in-three-upcoming-investor-conferences https://www.rigel.com/news-media/press-releases/detail/322/data-from-nihnhlbi-sponsored-phase-2-trial-of-fostamatinib https://www.rigel.com/news-media/press-releases/detail/321/rigel-pharmaceuticals-provides-update-on-covid-19-program https://www.rigel.com/news-media/press-releases/detail/320/rigel-reports-second-quarter-2021-financial-results-and https://www.rigel.com/news-media/press-releases/detail/319/rigel-announces-conference-call-and-webcast-to-report https://www.rigel.com/news-media/press-releases/detail/318/new-tavalisse-data-analyses-to-be-presented-at https://www.rigel.com/news-media/press-releases/detail/317/fostamatinib-selected-for-nih-activ-4-covid-19-clinical https://www.rigel.com/news-media/press-releases/detail/316/rigel-to-present-at-the-jefferies-virtual-healthcare https://www.rigel.com/news-media/press-releases/detail/315/rigel-appoints-alison-l-hannah-m-d-to-board-of-directors https://www.rigel.com/news-media/press-releases/detail/314/rigel-reports-first-quarter-2021-financial-results-and https://www.rigel.com/news-media/press-releases/detail/313/rigel-announces-conference-call-and-webcast-to-report-first https://www.rigel.com/news-media/press-releases/detail/312/positive-topline-data-shows-fostamatinib-meets-primary https://www.rigel.com/news-media/press-releases/detail/311/rigel-announces-closing-of-strategic-collaboration-with https://www.rigel.com/news-media/press-releases/detail/310/rigel-announces-completion-of-patient-enrollment-for https://www.rigel.com/news-media/press-releases/detail/309/rigel-reports-fourth-quarter-and-full-year-2020-financial https://www.rigel.com/news-media/press-releases/detail/308/rigel-announces-conference-call-and-webcast-to-report https://www.rigel.com/news-media/press-releases/detail/307/lilly-and-rigel-enter-strategic-collaboration-to-develop https://www.rigel.com/news-media/press-releases/detail/306/rigel-awarded-16-5-million-from-u-s-department-of-defense https://www.rigel.com/news-media/press-releases/detail/305/rigel-pharmaceuticals-provides-business-update https://www.rigel.com/news-media/press-releases/detail/304/rigel-to-present-at-the-39th-annual-j-p-morgan-healthcare https://www.rigel.com/news-media/press-releases/detail/303/rigel-announces-two-posters-highlighting-tavalisse-at-the https://www.rigel.com/news-media/press-releases/detail/302/rigel-and-medison-announce-health-canada-approval-of https://www.rigel.com/news-media/press-releases/detail/301/rigel-finalizes-the-study-design-of-its-ongoing-phase-3 https://www.rigel.com/news-media/press-releases/detail/300/rigel-to-present-at-the-jefferies-virtual-london-healthcare https://www.rigel.com/news-media/press-releases/detail/299/rigel-reports-third-quarter-2020-financial-results-and https://www.rigel.com/news-media/press-releases/detail/298/rigel-announces-conference-call-and-webcast-to-report-third https://www.rigel.com/news-media/press-releases/detail/297/rigel-announces-first-patients-enrolled-in https://www.rigel.com/news-media/press-releases/detail/296/rigel-announces-nihnhlbi-sponsored-trial-of-fostamatinib https://www.rigel.com/news-media/press-releases/detail/295/rigel-to-present-at-two-upcoming-investor-conferences https://www.rigel.com/news-media/press-releases/detail/294/rigel-to-participate-in-citis-15th-annual-biopharma https://www.rigel.com/news-media/press-releases/detail/292/rigel-reports-second-quarter-2020-financial-results https://www.rigel.com/news-media/press-releases/detail/291/rigel-announces-conference-call-and-webcast-to-report https://www.rigel.com/news-media/press-releases/detail/290/rigel-announces-post-hoc-data-analysis-of-tavalisse-in https://www.rigel.com/news-media/press-releases/detail/289/rigel-announces-investigator-sponsored-trial-of https://www.rigel.com/news-media/press-releases/detail/288/rigel-announces-availability-of-tavlesse-fostamatinib https://www.rigel.com/news-media/press-releases/detail/287/rigel-to-present-at-the-bmo-2020-prescriptions-for-success https://www.rigel.com/news-media/press-releases/detail/286/rigel-to-present-poster-highlighting-tavalisse-at-the https://www.rigel.com/news-media/press-releases/detail/285/rigel-to-present-four-posters-highlighting-irak14 https://www.rigel.com/news-media/press-releases/detail/284/rigel-to-present-at-the-jefferies-virtual-healthcare https://www.rigel.com/news-media/press-releases/detail/283/rigel-reports-first-quarter-2020-financial-results-and https://www.rigel.com/news-media/press-releases/detail/282/rigel-announces-change-to-virtual-format-for-2020-annual https://www.rigel.com/news-media/press-releases/detail/281/rigel-announces-conference-call-and-webcast-to-report-first https://www.rigel.com/news-media/press-releases/detail/280/rigel-reports-fourth-quarter-and-full-year-2019-financial https://www.rigel.com/news-media/press-releases/detail/279/rigel-announces-conference-call-and-webcast-to-report https://www.rigel.com/news-media/press-releases/detail/278/rigel-pharmaceuticals-provides-business-update https://www.rigel.com/news-media/press-releases/detail/277/rigel-to-present-at-the-38th-annual-j-p-morgan-healthcare https://www.rigel.com/news-media/press-releases/detail/276/rigel-announces-chief-commercial-officer-transition https://www.rigel.com/news-media/press-releases/detail/275/rigel-receives-positive-chmp-opinion-for-fostamatinib https://www.rigel.com/news-media/press-releases/detail/274/rigel-to-present-at-jefferies-2019-london-healthcare https://www.rigel.com/news-media/press-releases/detail/273/rigel-announces-upcoming-data-presentations-at-the-61st-ash https://www.rigel.com/news-media/press-releases/detail/272/rigel-announces-third-quarter-2019-financial-results https://www.rigel.com/news-media/press-releases/detail/271/rigel-announces-conference-call-and-webcast-to-report-third https://www.rigel.com/news-media/press-releases/detail/270/rigel-pharmaceuticals-provides-business-update-prior-to https://www.rigel.com/news-media/press-releases/detail/269/rigel-receives-positive-trend-vote-from-chmp-for https://www.rigel.com/news-media/press-releases/detail/268/rigel-to-host-investor-and-analyst-call-on-october-23-2019 https://www.rigel.com/news-media/press-releases/detail/267/rigel-secures-credit-facility-for-up-to-60-million https://www.rigel.com/news-media/press-releases/detail/266/rigels-fostamatinib-enters-phase-3-clinical-trial-in-japan https://www.rigel.com/news-media/press-releases/detail/265/rigels-ceo-to-participate-in-panel-discussion-at-citis https://www.rigel.com/news-media/press-releases/detail/264/rigel-announces-second-quarter-2019-financial-results-and https://www.rigel.com/news-media/press-releases/detail/262/rigel-announces-conference-call-and-webcast-to-report https://www.rigel.com/news-media/press-releases/detail/261/rigel-to-present-two-posters-highlighting-fostamatinib-at https://www.rigel.com/news-media/press-releases/detail/260/rigel-to-present-at-jefferies-2019-healthcare-conference https://www.rigel.com/news-media/press-releases/detail/259/rigel-enrolls-first-patient-in-phase-3-clinical-trial-of https://www.rigel.com/news-media/press-releases/detail/258/rigel-announces-first-quarter-2019-financial-results-and https://www.rigel.com/news-media/press-releases/detail/257/rigel-announces-conference-call-and-webcast-to-report-first https://www.rigel.com/news-media/press-releases/detail/256/rigel-welcomes-jane-wasman-to-board-of-directors https://www.rigel.com/news-media/press-releases/detail/255/rigel-reports-fourth-quarter-and-full-year-2018-financial https://www.rigel.com/news-media/press-releases/detail/254/rigel-announces-conference-call-and-webcast-to-report https://www.rigel.com/news-media/press-releases/detail/253/rigel-pharmaceuticals-enters-collaboration-and-license https://www.rigel.com/news-media/press-releases/detail/252/rigel-pharmaceuticals-provides-business-update https://www.rigel.com/news-media/press-releases/detail/251/rigel-to-present-at-the-37th-annual-j-p-morgan-healthcare https://www.rigel.com/news-media/press-releases/detail/250/rigel-to-present-at-the-bmo-capital-markets-2018 https://www.rigel.com/news-media/press-releases/detail/249/rigel-announces-third-quarter-2018-financial-results-and https://www.rigel.com/news-media/press-releases/detail/248/rigel-to-present-data-on-fostamatinib-in-three https://www.rigel.com/news-media/press-releases/detail/247/rigel-announces-conference-call-and-webcast-to-report-third https://www.rigel.com/news-media/press-releases/detail/246/rigel-pharmaceuticals-enters-collaboration-and-license https://www.rigel.com/news-media/press-releases/detail/245/rigel-receives-ema-validation-of-the-marketing https://www.rigel.com/news-media/press-releases/detail/244/rigel-to-host-investor-analyst-day-in-new-york-city-on https://www.rigel.com/news-media/press-releases/detail/243/rigel-to-present-at-the-cantor-global-healthcare-conference https://www.rigel.com/news-media/press-releases/detail/242/rigel-to-present-at-the-20th-annual-global-investment https://www.rigel.com/news-media/press-releases/detail/241/rigel-announces-second-quarter-2018-financial-results-and https://www.rigel.com/news-media/press-releases/detail/240/rigel-announces-conference-call-and-webcast-to-report https://www.rigel.com/news-media/press-releases/detail/239/rigel-initiates-phase-1-clinical-trial-of-r835-an-irak14 https://www.rigel.com/news-media/press-releases/detail/238/rigel-announces-poster-presentations-at-focis-annual-meeting https://www.rigel.com/news-media/press-releases/detail/237/rigel-to-present-phase-2-results-for-fostamatinib-in https://www.rigel.com/news-media/press-releases/detail/236/rigel-to-present-at-jefferies-2018-global-healthcare https://www.rigel.com/news-media/press-releases/detail/235/rigel-appoints-dean-schorno-as-chief-financial-officer https://www.rigel.com/news-media/press-releases/detail/234/rigel-announces-availability-of-tavalisse-fostamatinib https://www.rigel.com/news-media/press-releases/detail/233/rigel-announces-first-quarter-2018-financial-results-and https://www.rigel.com/news-media/press-releases/detail/232/tavalisse-fostamatinib-disodium-hexahydrate-phase-3 https://www.rigel.com/news-media/press-releases/detail/231/rigel-announces-conference-call-and-webcast-to-report-first https://www.rigel.com/news-media/press-releases/detail/230/rigel-announces-pricing-of-public-offering-of-common-stock https://www.rigel.com/news-media/press-releases/detail/229/rigel-announces-proposed-public-offering-of-common-stock https://www.rigel.com/news-media/press-releases/detail/228/rigel-announces-fda-approval-of-tavalisse-fostamatinib https://www.rigel.com/news-media/press-releases/detail/227/rigel-makes-statement-regarding-website-error https://www.rigel.com/news-media/press-releases/detail/226/rigel-announces-topline-data-from-proof-of-concept-phase-2 https://www.rigel.com/news-media/press-releases/detail/225/rigel-announces-fourth-quarter-and-year-end-2017-financial https://www.rigel.com/news-media/press-releases/detail/224/rigel-announces-two-fostamatinib-presentations-at-the-4th https://www.rigel.com/news-media/press-releases/detail/223/rigel-announces-conference-call-and-webcast-to-report https://www.rigel.com/news-media/press-releases/detail/222/rigel-pharmaceuticals-inc-announces-inducement-grant https://www.rigel.com/news-media/press-releases/detail/221/rigel-pharmaceuticals-inc-announces-inducement-grant https://www.rigel.com/news-media/press-releases/detail/220/rigel-pharmaceuticals-inc-announces-inducement-grant https://www.rigel.com/news-media/press-releases/detail/219/rigel-to-provide-business-review-and-updated-phase-2 https://www.rigel.com/news-media/press-releases/detail/218/rigel-announces-departure-of-chief-financial-officer https://www.rigel.com/news-media/press-releases/detail/217/rigel-pharmaceuticals-inc-announces-inducement-grant https://www.rigel.com/news-media/press-releases/detail/216/rigel-to-present-one-year-efficacy-and-safety-results-for https://www.rigel.com/news-media/press-releases/detail/215/rigel-pharmaceuticals-inc-announces-inducement-grants https://www.rigel.com/news-media/press-releases/detail/214/rigel-announces-third-quarter-2017-financial-results-and https://www.rigel.com/news-media/press-releases/detail/213/rigel-welcomes-gregg-lapointe-to-board-of-directors https://www.rigel.com/news-media/press-releases/detail/212/rigel-announces-conference-call-and-webcast-to-report-third https://www.rigel.com/news-media/press-releases/detail/211/rigel-announces-closing-of-public-offering-of-common-stock https://www.rigel.com/news-media/press-releases/detail/210/rigel-announces-pricing-of-public-offering-of-common-stock https://www.rigel.com/news-media/press-releases/detail/209/rigel-announces-proposed-public-offering-of-common-stock https://www.rigel.com/news-media/press-releases/detail/208/fostamatinib-meets-pre-specified-primary-endpoint-in-stage https://www.rigel.com/news-media/press-releases/detail/207/rigel-provides-update-on-fda-review-of-fostamatinib-for-itp https://www.rigel.com/news-media/press-releases/detail/206/rigel-to-present-at-cantor-fitzgerald-global-healthcare https://www.rigel.com/news-media/press-releases/detail/205/rigel-welcomes-brian-kotzin-m-d-to-board-of-directors https://www.rigel.com/news-media/press-releases/detail/204/rigel-pharmaceuticals-inc-announces-inducement-grants https://www.rigel.com/news-media/press-releases/detail/203/rigel-announces-second-quarter-2017-financial-results-and https://www.rigel.com/news-media/press-releases/detail/202/rigel-announces-conference-call-and-webcast-to-report https://www.rigel.com/news-media/press-releases/detail/201/rigel-announces-oral-presentation-of-tavalisse https://www.rigel.com/news-media/press-releases/detail/200/fda-accepts-rigels-new-drug-application-for-tavalisse https://www.rigel.com/news-media/press-releases/detail/199/rigel-to-present-at-jefferies-2017-global-healthcare https://www.rigel.com/news-media/press-releases/detail/198/rigel-announces-first-quarter-2017-financial-results-and https://www.rigel.com/news-media/press-releases/detail/197/rigel-announces-tavalisse-as-proprietary-name-for https://www.rigel.com/news-media/press-releases/detail/196/rigel-announces-conference-call-and-webcast-to-report-first https://www.rigel.com/news-media/press-releases/detail/195/rigel-submits-new-drug-application-to-fda-for-fostamatinib https://www.rigel.com/news-media/press-releases/detail/194/rigel-announces-fourth-quarter-2016-and-year-end-2016 https://www.rigel.com/news-media/press-releases/detail/193/rigel-announces-conference-call-and-webcast-to-report https://www.rigel.com/news-media/press-releases/detail/192/rigel-announces-closing-of-public-offering-of-common-stock https://www.rigel.com/news-media/press-releases/detail/191/rigel-announces-pricing-of-public-offering-of-common-stock https://www.rigel.com/news-media/press-releases/detail/190/rigel-announces-proposed-public-offering-of-common-stock https://www.rigel.com/news-media/press-releases/detail/189/fostamatinib-study-results-continue-to-trend-positive https://www.rigel.com/news-media/press-releases/detail/188/rigel-pharmaceuticals-inc-announces-inducement-grants https://www.rigel.com/news-media/press-releases/detail/187/rigel-provides-business-updates-and-preliminary-data-in-iga https://www.rigel.com/news-media/press-releases/detail/186/rigel-to-present-at-jefferies-2016-london-healthcare https://www.rigel.com/news-media/press-releases/detail/185/rigel-announces-third-quarter-2016-financial-results-and https://www.rigel.com/news-media/press-releases/detail/184/rigel-announces-conference-call-and-webcast-to-report-third https://www.rigel.com/news-media/press-releases/detail/183/rigel-announces-results-from-the-second-fit-phase-3-study https://www.rigel.com/news-media/press-releases/detail/182/rigel-pharmaceuticals-inc-announces-inducement-grants https://www.rigel.com/news-media/press-releases/detail/181/rigel-expands-leadership-team-in-research-and-business https://www.rigel.com/news-media/press-releases/detail/180/rigel-restructures-to-focus-on-fostamatinib https://www.rigel.com/news-media/press-releases/detail/179/rigels-fostamatinib-meets-primary-endpoint-in-phase-3 https://www.rigel.com/news-media/press-releases/detail/178/rigel-announces-press-release-and-conference-call-schedule https://www.rigel.com/news-media/press-releases/detail/177/rigel-announces-second-quarter-2016-financial-results-and https://www.rigel.com/news-media/press-releases/detail/176/rigel-announces-conference-call-and-webcast-to-report https://www.rigel.com/news-media/press-releases/detail/175/rigel-to-present-at-jefferies-2016-healthcare-conference https://www.rigel.com/news-media/press-releases/detail/174/rigel-to-present-at-upcoming-american-association-of https://www.rigel.com/news-media/press-releases/detail/173/rigel-announces-first-quarter-2016-financial-results https://www.rigel.com/news-media/press-releases/detail/172/rigel-announces-conference-call-and-webcast-to-report-first https://www.rigel.com/news-media/press-releases/detail/171/rigel-announces-presentations-at-upcoming-american https://www.rigel.com/news-media/press-releases/detail/170/rigel-completes-enrollment-of-fit-phase-3-program-for https://www.rigel.com/news-media/press-releases/detail/169/rigel-announces-fourth-quarter-and-year-end-2015-financial https://www.rigel.com/news-media/press-releases/detail/168/rigel-names-anne-marie-duliege-m-d-m-s-as-chief-medical https://www.rigel.com/news-media/press-releases/detail/167/rigel-announces-conference-call-and-webcast-to-report https://www.rigel.com/news-media/press-releases/detail/166/rigel-to-present-at-cowen-and-company-36th-annual-health https://www.rigel.com/news-media/press-releases/detail/165/rigel-initiates-phase-2-clinical-trial-of-fostamatinib-in https://www.rigel.com/news-media/press-releases/detail/164/rigel-completes-enrollment-of-first-phase-3-study-of https://www.rigel.com/news-media/press-releases/detail/163/rigel-reviews-recent-progress-and-announces-presentation-at https://www.rigel.com/news-media/press-releases/detail/162/rigel-announces-third-quarter-2015-financial-results https://www.rigel.com/news-media/press-releases/detail/161/rigel-announces-conference-call-and-webcast-to-report-third https://www.rigel.com/news-media/press-releases/detail/160/rigel-and-aclaris-therapeutics-international-sign-license https://www.rigel.com/news-media/press-releases/detail/159/rigel-granted-orphan-drug-designation-for-fostamatinib-in https://www.rigel.com/news-media/press-releases/detail/158/rigel-announces-second-quarter-2015-financial-results https://www.rigel.com/news-media/press-releases/detail/157/rigel-announces-conference-call-and-webcast-to-report https://www.rigel.com/news-media/press-releases/detail/156/rigel-welcomes-keith-a-katkin-to-board-of-directors https://www.rigel.com/news-media/press-releases/detail/155/rigel-to-present-at-jefferies-2015-global-healthcare https://www.rigel.com/news-media/press-releases/detail/154/rigel-announces-first-quarter-2015-financial-results https://www.rigel.com/news-media/press-releases/detail/153/rigel-announces-fourth-quarter-and-year-end-2014-financial https://www.rigel.com/news-media/press-releases/detail/152/rigel-and-bristol-myers-squibb-announce-research-and https://www.rigel.com/news-media/press-releases/detail/151/rigel-to-present-at-the-33rd-annual-j-p-morgan-healthcare https://www.rigel.com/news-media/press-releases/detail/150/rigel-announces-executive-management-changes https://www.rigel.com/news-media/press-releases/detail/149/rigel-announces-third-quarter-2014-financial-results https://www.rigel.com/news-media/press-releases/detail/147/r348-did-not-meet-endpoints-in-phase-2-dry-eye-study https://www.rigel.com/news-media/press-releases/detail/148/rigel-announces-second-quarter-2014-financial-results https://www.rigel.com/news-media/press-releases/detail/146/rigel-initiates-phase-3-studies-of-fostamatinib-in-itp https://www.rigel.com/news-media/press-releases/detail/144/rigel-to-present-at-jefferies-2014-global-healthcare https://www.rigel.com/news-media/press-releases/detail/145/rigel-announces-first-quarter-2014-financial-results https://www.rigel.com/news-media/press-releases/detail/143/rigel-announces-webcast-of-investor-day-on-may-6-2014 https://www.rigel.com/news-media/press-releases/detail/142/rigel-announces-publication-of-r118-ampk-activator-research https://www.rigel.com/news-media/press-releases/detail/141/rigel-announces-fourth-quarter-and-year-end-2013-financial https://www.rigel.com/news-media/press-releases/detail/140/rigel-announces-participation-at-two-investor-conferences https://www.rigel.com/news-media/press-releases/detail/139/rigel-announces-participation-at-two-investor-conferences https://www.rigel.com/news-media/press-releases/detail/138/rigel-will-present-clinical-product-portfolio-update-at https://www.rigel.com/news-media/press-releases/detail/137/rigel-to-present-at-oppenheimer-healthcare-conference https://www.rigel.com/news-media/press-releases/detail/136/rigel-announces-third-quarter-2013-financial-results https://www.rigel.com/news-media/press-releases/detail/135/rigel-provides-pipeline-update https://www.rigel.com/news-media/press-releases/detail/133/rigel-to-present-at-stifel-healthcare-conference https://www.rigel.com/news-media/press-releases/detail/134/rigel-to-focus-on-itp-dle-and-dry-eye https://www.rigel.com/news-media/press-releases/detail/132/rigels-r343-did-not-meet-primary-endpoint-in-asthma-study https://www.rigel.com/news-media/press-releases/detail/131/rigel-announces-second-quarter-2013-financial-results https://www.rigel.com/news-media/press-releases/detail/4/rigel-will-resume-responsibility-for-fostamatinib-program https://www.rigel.com/news-media/press-releases/detail/42/rigels-r348-to-initiate-phase-2-clinical-trial-in-dry-eye https://www.rigel.com/news-media/press-releases/detail/41/rigel-announces-first-quarter-2013-financial-results https://www.rigel.com/news-media/press-releases/detail/45/astrazeneca-announces-top-line-results-from-oskira-1-phase https://www.rigel.com/news-media/press-releases/detail/63/rigel-announces-fourth-quarter-and-year-end-2012-financial https://www.rigel.com/news-media/press-releases/detail/112/rigel-announces-participation-at-two-investor-conferences https://www.rigel.com/news-media/press-releases/detail/111/rigel-to-present-at-bio-ceo-investor-conference https://www.rigel.com/news-media/press-releases/detail/12/rigel-to-focus-on-extensive-clinical-pipeline-at-upcoming https://www.rigel.com/news-media/press-releases/detail/22/astrazeneca-announces-top-line-results-of-oskira-4-phase https://www.rigel.com/news-media/press-releases/detail/58/rigel-announces-pricing-of-public-offering-of-common-stock https://www.rigel.com/news-media/press-releases/detail/57/rigel-announces-proposed-public-offering-of-common-stock https://www.rigel.com/news-media/press-releases/detail/67/rigel-to-present-at-ubs-global-life-sciences-conference https://www.rigel.com/news-media/press-releases/detail/66/rigel-initiates-phase-2-clinical-studies-with-r343-for https://www.rigel.com/news-media/press-releases/detail/68/rigel-announces-second-quarter-2012-financial-results https://www.rigel.com/news-media/press-releases/detail/121/astrazeneca-and-rigel-sign-worldwide-license-agreement-for https://www.rigel.com/news-media/press-releases/detail/13/rigel-announces-participation-at-two-investor-conferences https://www.rigel.com/news-media/press-releases/detail/14/rigel-advances-asthma-programs-two-inhaled-drug-candidates https://www.rigel.com/news-media/press-releases/detail/15/rigel-announces-first-quarter-2012-financial-results https://www.rigel.com/news-media/press-releases/detail/122/rigel-announces-fourth-quarter-and-year-end-2011-financial https://www.rigel.com/news-media/press-releases/detail/69/rigel-announces-participation-at-two-investor-conferences https://www.rigel.com/news-media/press-releases/detail/77/rigel-announces-initiation-of-clinical-trials-in-two https://www.rigel.com/news-media/press-releases/detail/59/rigel-to-present-at-oppenheimer-annual-healthcare-conference https://www.rigel.com/news-media/press-releases/detail/9/rigel-to-webcast-investor-day-on-october-13-2011 https://www.rigel.com/news-media/press-releases/detail/24/rigel-to-present-at-two-upcoming-investor-conferences https://www.rigel.com/news-media/press-releases/detail/23/rigel-announces-second-quarter-2011-financial-results https://www.rigel.com/news-media/press-releases/detail/117/rigel-to-present-at-wells-fargo-securities-healthcare https://www.rigel.com/news-media/press-releases/detail/116/rigel-to-present-at-jefferies-global-healthcare-conference https://www.rigel.com/news-media/press-releases/detail/38/rigel-announces-pricing-of-public-offering-of-common-stock https://www.rigel.com/news-media/press-releases/detail/36/rigel-announces-proposed-public-offering-of-common-stock https://www.rigel.com/news-media/press-releases/detail/37/rigel-assumes-development-responsibility-for-inhaled-asthma https://www.rigel.com/news-media/press-releases/detail/40/rigel-to-present-at-bank-of-america-merrill-lynch-health https://www.rigel.com/news-media/press-releases/detail/39/rigel-announces-first-quarter-financial-results https://www.rigel.com/news-media/press-releases/detail/113/rigel-announces-fourth-quarter-and-year-end-2010-financial https://www.rigel.com/news-media/press-releases/detail/5/rigel-to-present-at-three-upcoming-investor-conferences https://www.rigel.com/news-media/press-releases/detail/6/rigel-announces-participation-at-two-investor-conferences https://www.rigel.com/news-media/press-releases/detail/46/rigel-to-present-at-jp-morgan-healthcare-conference https://www.rigel.com/news-media/press-releases/detail/98/rigel-and-astrazeneca-awarded-licensing-deal-of-the-year https://www.rigel.com/news-media/press-releases/detail/129/rigel-to-present-at-piper-jaffray-health-care-conference https://www.rigel.com/news-media/press-releases/detail/130/rigel-announces-third-quarter-2010-financial-results https://www.rigel.com/news-media/press-releases/detail/54/rigel-announces-presentations-at-two-investor-conferences https://www.rigel.com/news-media/press-releases/detail/44/rigel-earns-milestone-payments-from-astrazeneca https://www.rigel.com/news-media/press-releases/detail/43/rigel-to-present-at-stifel-nicolaus-healthcare-conference https://www.rigel.com/news-media/press-releases/detail/16/rigel-announces-second-quarter-2010-financial-results https://www.rigel.com/news-media/press-releases/detail/118/rigel-to-present-at-bmo-capital-markets-healthcare https://www.rigel.com/news-media/press-releases/detail/18/rigel-announces-presentation-at-three-investor-conferences https://www.rigel.com/news-media/press-releases/detail/17/rigel-pharmaceuticals-names-raul-rodriguez-president https://www.rigel.com/news-media/press-releases/detail/1/rigel-announces-first-quarter-2010-financial-results https://www.rigel.com/news-media/press-releases/detail/19/rigel-receives-innovators-award-of-excellence-in-life https://www.rigel.com/news-media/press-releases/detail/90/rigel-announces-expiry-of-waiting-period-under https://www.rigel.com/news-media/press-releases/detail/87/rigel-to-webcast-investor-day-on-march-25-2010 https://www.rigel.com/news-media/press-releases/detail/88/rigel-to-present-at-barclays-capital-healthcare-conference https://www.rigel.com/news-media/press-releases/detail/89/rigel-to-present-at-cowen-and-company-health-care-conference https://www.rigel.com/news-media/press-releases/detail/91/rigel-announces-fourth-quarter-and-year-end-2009-financial https://www.rigel.com/news-media/press-releases/detail/108/rigel-to-host-conference-call-today-to-discuss-its https://www.rigel.com/news-media/press-releases/detail/109/astrazeneca-and-rigel-pharmaceuticals-sign-worldwide https://www.rigel.com/news-media/press-releases/detail/110/rigel-to-present-at-bio-ceo-investor-conference https://www.rigel.com/news-media/press-releases/detail/94/rigel-receives-milestone-payment-from-daiichi-sankyo-for https://www.rigel.com/news-media/press-releases/detail/93/eleven-rigel-product-candidate-presentations-at-2009-ash https://www.rigel.com/news-media/press-releases/detail/103/rigel-announces-third-quarter-2009-financial-results https://www.rigel.com/news-media/press-releases/detail/123/rigel-announces-presentations-at-two-investor-conferences https://www.rigel.com/news-media/press-releases/detail/124/rigel-to-webcast-analyst-briefing-on-october-20-2009 https://www.rigel.com/news-media/press-releases/detail/10/rigel-announces-pricing-of-public-offering-of-13000000 https://www.rigel.com/news-media/press-releases/detail/11/rigel-announces-proposed-offering-of-6000000-shares-of https://www.rigel.com/news-media/press-releases/detail/92/rigel-announces-second-quarter-2009-financial-results https://www.rigel.com/news-media/press-releases/detail/35/r788-in-taski3-clinical-trial-does-not-meet-efficacy https://www.rigel.com/news-media/press-releases/detail/33/rigel-to-host-conference-call-to-discuss-results-of-its https://www.rigel.com/news-media/press-releases/detail/34/rigels-r788-significantly-improves-rheumatoid-arthritis-in https://www.rigel.com/news-media/press-releases/detail/32/rigel-to-host-conference-call-to-discuss-results-of-its https://www.rigel.com/news-media/press-releases/detail/21/rigel-to-present-at-jefferies-healthcare-conference https://www.rigel.com/news-media/press-releases/detail/20/rigels-r788-evaluated-in-phase-2-trial-in-multiple-cancers https://www.rigel.com/news-media/press-releases/detail/78/rigel-to-present-at-jmp-securities-research-conference https://www.rigel.com/news-media/press-releases/detail/79/rigel-announces-first-quarter-2009-financial-results https://www.rigel.com/news-media/press-releases/detail/28/rigel-announces-fourth-quarter-and-year-end-2008-financial https://www.rigel.com/news-media/press-releases/detail/27/rigel-to-present-at-bio-ceo-investor-conference https://www.rigel.com/news-media/press-releases/detail/29/rigel-expects-r788-partnership-after-phase-2b-clinical https://www.rigel.com/news-media/press-releases/detail/26/rigel-to-host-conference-call-on-february-3-2009 https://www.rigel.com/news-media/press-releases/detail/65/rigel-to-present-at-keystone-symposia-conference https://www.rigel.com/news-media/press-releases/detail/114/rigel-to-participate-at-the-rbc-capital-markets-healthcare https://www.rigel.com/news-media/press-releases/detail/115/rigel-to-host-conference-call-to-discuss-phase-2-study https://www.rigel.com/news-media/press-releases/detail/82/rigel-to-present-at-the-piper-jaffray-annual-health-care https://www.rigel.com/news-media/press-releases/detail/80/rigels-r788-phase-2a-results-published-in-arthritis-and https://www.rigel.com/news-media/press-releases/detail/81/rigel-to-present-at-the-2008-credit-suisse-healthcare https://www.rigel.com/news-media/press-releases/detail/83/rigel-announces-third-quarter-2008-financial-results-and https://www.rigel.com/news-media/press-releases/detail/106/rigel-to-host-update-conference-call https://www.rigel.com/news-media/press-releases/detail/105/rigel-to-present-at-the-oppenheimer-19th-annual-healthcare https://www.rigel.com/news-media/press-releases/detail/107/rigel-to-webcast-investor-update-on-october-27-2008 https://www.rigel.com/news-media/press-releases/detail/104/rigel-to-present-at-jmp-securities-healthcare-focused https://www.rigel.com/news-media/press-releases/detail/120/rigel-to-present-at-thomas-weisel-partners-healthcare https://www.rigel.com/news-media/press-releases/detail/25/rigel-to-present-at-collins-stewart-growth-conference https://www.rigel.com/news-media/press-releases/detail/128/rigel-to-present-at-jefferies-healthcare-conference https://www.rigel.com/news-media/press-releases/detail/127/rigel-initiates-two-phase-2b-clinical-trials-of-r788-in https://www.rigel.com/news-media/press-releases/detail/126/rigel-to-present-at-the-needham-biotechnology-and-medical https://www.rigel.com/news-media/press-releases/detail/263/preliminary-phase-2-results-of-r788-in-lymphoma-show https://www.rigel.com/news-media/press-releases/detail/125/rigel-to-host-conference-call-to-discuss-preliminary-phase https://www.rigel.com/news-media/press-releases/detail/64/rigel-announces-first-quarter-2008-financial-results https://www.rigel.com/news-media/press-releases/detail/8/rigel-to-present-at-8th-annual-fortis-bank-biotechnology https://www.rigel.com/news-media/press-releases/detail/7/rigel-announces-participation-in-upcoming-investor-and https://www.rigel.com/news-media/press-releases/detail/95/daniel-magilavy-m-d-joins-rigel-as-vice-president-of https://www.rigel.com/news-media/press-releases/detail/96/rigel-announces-fourth-quarter-and-year-end-2007-financial https://www.rigel.com/news-media/press-releases/detail/97/rigel-to-present-at-bio-ceo-investor-conference https://www.rigel.com/news-media/press-releases/detail/49/rigel-announces-pricing-of-public-offering-of-common-stock https://www.rigel.com/news-media/press-releases/detail/50/rigel-announces-offering-of-4000000-shares-of-common-stock https://www.rigel.com/news-media/press-releases/detail/48/rigel-to-present-programs-at-four-upcoming-scientific https://www.rigel.com/news-media/press-releases/detail/47/rigel-announces-initiation-of-phase-1-clinical-trial-of https://www.rigel.com/news-media/press-releases/detail/52/rigels-r788-demonstrates-significant-improvement-in https://www.rigel.com/news-media/press-releases/detail/53/rigel-announces-initiation-of-phase-1-clinical-trial-of https://www.rigel.com/news-media/press-releases/detail/51/rigel-announces-presentations-at-the-2007-american-society https://www.rigel.com/news-media/press-releases/detail/76/rigel-to-host-conference-call-to-discuss-phase-2-study https://www.rigel.com/news-media/press-releases/detail/74/merck-serono-exercises-option-to-rigels-r763as703569-and https://www.rigel.com/news-media/press-releases/detail/75/rigel-r788-raises-platelet-counts-in-immune https://www.rigel.com/news-media/press-releases/detail/73/rigel-announces-third-quarter-2007-financial-results https://www.rigel.com/news-media/press-releases/detail/56/rigel-announces-presentations-at-upcoming-investor-and https://www.rigel.com/news-media/press-releases/detail/55/rigel-to-present-research-programs-at-scientific-conferences https://www.rigel.com/news-media/press-releases/detail/30/rigel-announces-presentations-at-two-investor-conferences https://www.rigel.com/news-media/press-releases/detail/31/rigel-announces-second-quarter-2007-financial-results https://www.rigel.com/news-media/press-releases/detail/119/rigel-announces-start-of-phase-1-combination-therapy-study https://www.rigel.com/news-media/press-releases/detail/3/rigel-to-present-at-jefferies-healthcare-conference https://www.rigel.com/news-media/press-releases/detail/2/rigel-to-present-at-needham-biotechnology-conference https://www.rigel.com/news-media/press-releases/detail/60/rigel-to-present-at-jmp-securities-research-conference https://www.rigel.com/news-media/press-releases/detail/61/rigel-announces-pricing-of-public-offering-of-common-stock https://www.rigel.com/news-media/press-releases/detail/86/rigel-announces-offering-of-5000000-shares-of-common-stock https://www.rigel.com/news-media/press-releases/detail/85/rigel-to-present-new-research-programs-at-aacr-meeting https://www.rigel.com/news-media/press-releases/detail/84/rigel-provides-clinical-update-of-r788-phase-2-trials-in https://www.rigel.com/news-media/press-releases/detail/62/rigel-announces-presentation-at-the-lehman-brothers-global https://www.rigel.com/news-media/press-releases/detail/100/rigel-announces-initiation-of-phase-1-study-evaluating-r763 https://www.rigel.com/news-media/press-releases/detail/99/rigel-to-present-at-bio-ceo-investor-conference-2007 https://www.rigel.com/news-media/press-releases/detail/102/rigel-announces-fourth-quarter-and-year-end-2006-financial https://www.rigel.com/news-media/press-releases/detail/101/rigel-to-present-at-upcoming-scientific-conferences https://www.rigel.com/news-media/press-releases/detail/70/rigel-appoints-bradford-s-goodwin-to-board-of-directors https://www.rigel.com/news-media/press-releases/detail/71/rigel-announces-initiation-of-phase-ii-study-evaluating https://www.rigel.com/news-media/press-releases/detail/72/rigel-to-present-at-upcoming-keystone-symposium https://www.rigel.com/investors https://www.rigel.com/investors/news-events https://www.rigel.com/contact-us https://www.rigel.com/terms-of-use https://www.rigel.com/privacy-policy https://www.rigel.comjavascript:Cookiebot.renew()